← Back to Search

Alpha-glucosidase inhibitor

Acarbose for Healthy Subjects

Phase 4
Waitlist Available
Led By Juyun Lim
Research Sponsored by Oregon State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is looking at how different concentrations of saliva affect people's ability to taste glucose polymers, and how this affects their eating habits.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Detection of glucose polymers in the presence of acarbose

Side effects data

From 2016 Phase 4 trial • 494 Patients • NCT02049814
9%
Flatulence
6%
Urinary tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Metformin + Voglibose 0.2 mg
Metformin + Acarbose 50 mg

Trial Design

1Treatment groups
Experimental Treatment
Group I: AcarboseExperimental Treatment1 Intervention
Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acarbose
2015
Completed Phase 4
~15530

Find a Location

Who is running the clinical trial?

Oregon State UniversityLead Sponsor
49 Previous Clinical Trials
8,224 Total Patients Enrolled
Juyun LimPrincipal Investigator - Oregon State University
Oregon State University
1 Previous Clinical Trials
19 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the cap on participation for this clinical investigation?

"Affirmative. The information collated on clinicaltrials.gov implies that this research initiative is actively seeking participants, with the trial first posted on April 21st 2017 and updated as recently as April 18th 2022; 300 individuals are required at one location."

Answered by AI

Is the eligibility for this trial restricted to any age demographic?

"Patients aged 18 to 60 are eligible for participation in this trial."

Answered by AI

Has Acarbose been granted authorization by the Federal Drug Administration?

"Acarbose has been approved by the FDA, so it merited a score of 3 on our safety scale."

Answered by AI

Are there any vacancies for individuals to participate in this scientific trial?

"Affirmative. Clinicaltrials.gov reveals that this research initiative, initially posted on April 21st 2017, is currently recruiting participants. They are looking to onboard 300 individuals from one trial site."

Answered by AI

Is enrolment for this clinical research open to the public?

"This medical study necessitates that applicants possess healthy subject (hs) status and are between 18 to 60 years old. In total, 300 people will be accepted into the trial."

Answered by AI

Who else is applying?

What state do they live in?
Oregon
How old are they?
18 - 65
What site did they apply to?
Department of Food Science and Technology
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Human Oral Detection of Glucose Olygomers
Juyun Lim 2017. "Human Oral Detection of Glucose Olygomers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02589353.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top